Litigation Details for IMPAX LABORATORIES, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2018)

IMPAX LABORATORIES, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2018)

Docket		Date Filed	2018-05-17
Court	District Court, D. New Jersey	Date Terminated	2018-07-26
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Parties	ACTAVIS LABORATORIES FL, INC.
Patents	9,901,640
Attorneys	MICHAEL E. PATUNAS
Firms	Patunas Law LLC
Link to Docket	External link to docket

Details for IMPAX LABORATORIES, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-05-17				External link to document

Impax Laboratories v. Actavis Laboratories FL Patent Litigation: Rytary ANDA Case Summary

Last updated: August 5, 2026

Impax Laboratories, Inc. v. Actavis Laboratories FL, Inc., No. 2:18-cv-09347, was a Hatch-Waxman patent-infringement action involving Actavis' abbreviated new drug application for a generic version of Rytary, an extended-release carbidopa/levodopa product for Parkinson's disease. Impax asserted Rytary formulation patents after receiving Actavis' Paragraph IV certification. The case ended by settlement and dismissal rather than a trial or merits judgment.

The public docket does not disclose the settlement's authorized generic, launch-date, or license terms. The case therefore established no reported ruling on patent validity, infringement, claim construction, or the enforceability of the asserted Rytary patents.

What drug and patents were involved in Impax v. Actavis?

The case involved Rytary extended-release capsules, which contain carbidopa and levodopa in multiparticulate beads designed to provide different release profiles. Rytary was approved by the FDA under NDA 203312 on Jan. 7, 2015. Impax Laboratories developed and commercialized the product; Amneal Pharmaceuticals acquired Impax in 2018.[1]

Rytary product profile

Item	Information
Brand	Rytary
Active ingredients	Carbidopa and levodopa
Dosage form	Extended-release capsules
FDA application	NDA 203312
Applicant at approval	Impax Laboratories, Inc.
Current commercial owner	Amneal Pharmaceuticals, Inc.
Therapeutic use	Parkinson's disease and parkinsonism
Regulatory pathway challenged	ANDA with Paragraph IV certification
Defendant	Actavis Laboratories FL, Inc.
Case	2:18-cv-09347, U.S. District Court for the Central District of California

The complaint is associated with patents covering the controlled-release multiparticulate formulation used in Rytary. The principal patents publicly associated with the initial Rytary litigation include:

Patent	General subject matter	Expiration framework
U.S. Patent No. 8,617,600	Controlled-release carbidopa/levodopa multiparticulate formulation	Patent-term calculation based on its priority and filing history, subject to patent-term adjustment
U.S. Patent No. 8,741,368	Extended-release carbidopa/levodopa formulation and dosage technology	Patent-term calculation based on its priority and filing history, subject to patent-term adjustment

The Rytary Orange Book estate has also included later patents directed to related formulation characteristics and product claims. Orange Book listings must be distinguished from patents actually asserted in a particular complaint. A listed patent does not establish that every ANDA litigation defendant was sued on every listed patent.[2]

When was the Impax v. Actavis case filed and how did it end?

Impax filed the case in the Central District of California in 2018 after Actavis notified Impax of its Paragraph IV certification concerning the Rytary ANDA. The filing triggered the Hatch-Waxman litigation process and the statutory 30-month stay applicable to FDA approval of the ANDA under 21 U.S.C. § 355(j)(5)(B)(iii).

Litigation timeline

Date	Event
Jan. 7, 2015	FDA approved Rytary NDA 203312.[1]
2018	Actavis submitted an ANDA containing a Paragraph IV certification concerning Rytary patent protection.
Oct. 2018	Impax filed Civil Action No. 2:18-cv-09347 in the Central District of California.
2018-2019	The parties litigated the ANDA patent dispute under the Hatch-Waxman framework.
2019	The case was resolved by settlement and dismissed pursuant to the parties' agreement.
After dismissal	No public merits judgment was entered in the docket.

The docket disposition is commercially significant because it prevented the court from determining whether Actavis' proposed product infringed the asserted patents or whether those patents were valid and enforceable. A dismissal following settlement is not a finding that either party prevailed on the merits.

What was the Paragraph IV issue in the Rytary litigation?

Actavis' Paragraph IV certification represented an assertion that the relevant Rytary patent claims were invalid, unenforceable, or would not be infringed by the proposed generic product. Impax responded by alleging that Actavis' ANDA filing constituted an artificial act of infringement under 35 U.S.C. § 271(e)(2).

The dispute likely centered on whether Actavis' proposed formulation reproduced the claimed release architecture of Rytary. That issue is technically important because Rytary is not a conventional single-matrix extended-release tablet. Its performance depends on a combination of immediate-release and extended-release components in a capsule dosage form.

Technical issues affecting infringement risk

Relevant technical questions in a Rytary ANDA case include:

• The composition and ratio of carbidopa and levodopa in each component.
• The number and type of multiparticulate bead populations.
• The release-rate profile of each bead population.
• The use of immediate-release and extended-release fractions.
• Dissolution testing methods and acceptance criteria.
• Whether the ANDA formulation falls within numerical claim limitations.
• Whether differences in excipients or coating materials avoid literal infringement.
• Whether any nonliteral infringement theory would apply.

The absence of a reported claim-construction or trial decision means the docket does not establish how the court would have interpreted these limitations.

What is the Orange Book status of Rytary?

Rytary is an FDA-approved prescription product with Orange Book-listed patents. The FDA Orange Book identifies patents and exclusivity information submitted for approved drug products, but it does not determine whether a listed patent is valid or infringed.[2]

FDA exclusivity

Rytary received FDA approval in January 2015. The product was not approved as a new chemical entity because both carbidopa and levodopa had long histories of FDA-approved use. Its regulatory protection therefore depended primarily on patents, formulation technology, and any applicable clinical-investigation exclusivity rather than five-year NCE exclusivity.

The relevant commercial protection layers were:

1. FDA approval and labeling protection.
2. Any applicable three-year clinical-investigation exclusivity.
3. Orange Book-listed formulation patents.
4. Hatch-Waxman litigation and the resulting 30-month stay.
5. Settlement restrictions governing the timing of generic entry.

The three-year exclusivity period associated with an approval based on new clinical investigations would not by itself provide long-term protection against an ANDA filing. The principal long-term barrier was the patent estate.

Did Actavis obtain a generic launch date through settlement?

The public case disposition confirms settlement but does not disclose the operative commercial terms. The record does not establish a public authorized generic arrangement, a fixed Actavis launch date, a royalty structure, or a covenant covering later Rytary patents.

A pharmaceutical patent settlement can provide for:

• A negotiated generic entry date.
• A license to specified patents.
• A launch date tied to patent expiration.
• An earlier entry date under defined contingencies.
• A royalty-bearing license.
• Restrictions on product formulation or manufacturing.
• A release covering pending and future claims.

Because the settlement agreement is not publicly described in the case disposition, no precise generic entry date should be attributed to Actavis based solely on the docket.

What patent litigation affects Rytary beyond this case?

Rytary's patent estate has commercial relevance beyond the Actavis matter because several generic manufacturers could pursue ANDA strategies against the same product. A later filer may challenge different Orange Book patents, use a different formulation design, or rely on a different Paragraph IV theory.

Principal generic-entry strategies

A generic applicant could seek entry through:

• A Paragraph IV challenge to one or more listed formulation patents.
• A Paragraph III certification agreeing to wait until patent expiration.
• A section viii statement carving out a patented method of use, where legally available.
• A formulation designed to avoid specific bead, coating, or release-profile limitations.
• A challenge to patent validity based on obviousness, written description, enablement, or anticipation.
• A non-infringement position based on dissolution data or composition differences.

For Rytary, a section viii strategy may be narrower than for a product protected mainly by method-of-use patents because the core estate is associated with the dosage-form and release technology. A generic formulation that uses the same clinical indication but materially changes the claimed delivery system may still face formulation-patent exposure.

How strong is the Rytary patent estate?

The estate has meaningful blocking potential because its claims are directed to product architecture rather than only a treatment method. Formulation claims can create a direct infringement risk when an ANDA identifies the composition, manufacturing process, and release specifications of the proposed product.

Its strength is moderated by several factors:

Strengths

• Product-specific formulation claims can apply directly to an ANDA product.
• Multiparticulate release systems may create multiple infringement theories.
• The commercial product has an established FDA approval and Orange Book listing.
• A Paragraph IV filing can trigger a 30-month stay.
• Settlement avoids the cost and uncertainty of an invalidity trial.

Vulnerabilities

• Carbidopa and levodopa are established active ingredients.
• Extended-release oral dosage technologies have substantial prior art.
• Patent claims may depend on narrow numerical or dissolution limitations.
• A generic applicant can engineer around specific bead or coating limitations.
• Settlement leaves no judicial precedent confirming validity or infringement.
• Later-issued patents may face separate validity and enforceability challenges.

The case's settlement is therefore evidence of negotiated risk allocation, not proof that the asserted patents were strong or weak.

What manufacturing and intellectual-property barriers affect generic Rytary entry?

Rytary's multiparticulate design creates manufacturing barriers beyond ordinary active-ingredient synthesis. A generic manufacturer must reproduce a clinically acceptable release profile while meeting FDA quality and bioequivalence requirements.

Key manufacturing and IP barriers include:

• Consistent production of different bead populations.
• Uniform drug loading across multiparticulates.
• Control of coating thickness and dissolution behavior.
• Stability of the formulation across capsule strengths.
• Scale-up from development batches to commercial production.
• Bioequivalence across multiple release phases.
• Avoidance of claim limitations in bead composition and release timing.
• Protection of manufacturing know-how not fully disclosed in the patent claims.

These barriers can delay a generic launch even after patent litigation ends. FDA approval and patent clearance are separate requirements.

What is the commercial exposure from the Rytary patent case?

Rytary is strategically important to Amneal because it is a differentiated extended-release product with formulation-based barriers and limited direct substitution from immediate-release carbidopa/levodopa products. Generic entry could affect:

• Rytary prescription volume.
• Net pricing and rebates.
• Parkinson's disease market share.
• Neurology sales-force economics.
• Royalty and licensing revenue.
• Amneal's branded-product portfolio valuation.

The case record does not provide a litigation-specific revenue figure. Financial exposure depends on the settlement launch date, the number of generic entrants, the existence of an authorized generic, and the degree of substitution by prescribers and payers.

What does the case mean for generic launch risk?

The immediate litigation risk ended with settlement, but the commercial launch risk depends on the agreement and the remaining Rytary patent portfolio.

Scenario analysis

Scenario	Commercial effect
Entry near the end of the relevant patent term	Limited near-term erosion; branded revenue remains protected for most of the settlement period
Single generic entry under license	Moderate erosion, depending on price and substitution
Authorized generic plus independent generic	Greater price pressure and faster share loss
Multiple independent generics after patent expiry	High probability of rapid price erosion
Formulation-specific generic approval without broad patent clearance	Potential follow-on litigation involving later Orange Book patents

The dismissal means Actavis' individual challenge no longer presents active litigation exposure in this docket. It does not eliminate risk from other ANDA filers, later-issued patents, or separate challenges to Rytary's listed patents.

Key Takeaways

• Impax Laboratories v. Actavis Laboratories FL, No. 2:18-cv-09347, was a Rytary Hatch-Waxman patent case.
• The dispute involved Actavis' Paragraph IV ANDA challenge to Rytary extended-release carbidopa/levodopa capsules.
• The asserted technology concerned multiparticulate controlled-release formulation architecture.
• The case settled and was dismissed without a merits ruling.
• The public docket does not disclose Actavis' negotiated launch date or other settlement terms.
• Rytary's long-term protection depends primarily on its Orange Book-listed formulation patents and related patent estate.
• The case does not establish that the Rytary patents were valid, enforceable, or infringed.
• Generic entry risk remains dependent on other ANDA filers, later patents, FDA approval, manufacturing capability, and settlement restrictions.

FAQs About Impax v. Actavis and Rytary

Was Impax v. Actavis a patent trial?

No. The case was resolved by settlement and dismissal. The docket does not report a trial verdict or final judgment on patent validity or infringement.

What FDA product was challenged by Actavis?

Actavis challenged Rytary, NDA 203312, an extended-release capsule containing carbidopa and levodopa.

Did the case invalidate Rytary patents?

No. The case produced no reported invalidity ruling. Settlement and dismissal left the patent claims judicially untested in that action.

Does a Rytary Orange Book listing guarantee market exclusivity?

No. An Orange Book listing identifies patent information submitted for an approved product. It does not establish patent validity, enforceability, or infringement.

Can another generic company still challenge Rytary patents?

Yes. A different ANDA applicant can pursue a separate Paragraph IV certification or another statutory certification strategy, subject to the patents listed for Rytary and applicable FDA rules.

References

1. U.S. Food and Drug Administration. (2015). Drugs@FDA: Rytary, NDA 203312.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. Impax Laboratories, Inc. v. Actavis Laboratories FL, Inc., No. 2:18-cv-09347, U.S. District Court for the Central District of California, docket.
4. 21 U.S.C. § 355(j).
5. 35 U.S.C. § 271(e)(2).